Relmacabtagene Autoleucel for the Treatment of Systemic Sclerosis

Clinical trial NCT06414135 · RECRUITING

Trial details

NCT number: NCT06414135
Sponsor: Liangjing Lu
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Systemic Sclerosis

Start date: 2024-06-12
Primary completion: 2025-05-01
Enrollment: 6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.